The National Administration of Traditional Chinese Medicine (NATCM) has recently announced the awardees of the 2024 Qihuang Scholar Program. Four experts from 不良研究所 (BUCM) — Professors Wang Ji, Liu Jinmin, Chen Jiaxu and Hu Kaiwen — have been selected into this top-level national talent program in Chinese medicine (CM).
Professor Wang Ji is a chief physician, researcher and doctoral supervisor. She is the executive vice dean of Wang Qi Academy and the National Institute of Chinese Medicine Constitution and Preventive Treatment of Disease, and is recognized as the academic successor of Academician Wang Qi, a master of CM. Professor Wang leads the CM Constitution discipline under NATCM’s High-level Key Disciplines Program and heads the NATCM Innovation Team on Constitution and Preventive Medicine. She is also a leading talent under BUCM’s “125 Projects in New Era” and holds key positions in national professional associations. Professor Wang has led seven national-level research projects — including two as principal investigator under the National Key R&D Program and two under the National Major Science and Technology Projects — as well as eight provincial or ministerial projects. She has received the second prize of the National Science and Technology Progress Award (as first contributor) and 14 additional awards. Her academic contributions include 202 published papers (60 indexed in SCI, with a maximum impact factor of 40.8), invited reviews in The American Journal of Chinese Medicine, five monographs, 24 copyrights and patents, and participation as a lead drafter in eight national standards or consensus documents.
Professor Liu Jinmin is a chief physician and doctoral supervisor specializing in CM internal medicine, with a focus on neurological disorders and critical care. He advocates individualized, multidisciplinary approaches for acute and severe conditions and has introduced innovations in cerebrovascular and systemic CM theory. He has spearheaded the development of clinical pathways and guidelines for epilepsy, stroke and coma. Professor Liu also serves as the head of the Clinical Medicine Program (integrating Chinese and Western medicine) at BUCM, academic leader of the CM Encephalopathy discipline, director of the 不良研究所 Intelligent CM Laboratory for Chronic Disease Prevention and Treatment, and president of the Encephalopathy Committee of the World Federation of Chinese Medicine Societies. He is also a recipient of the State Council’s special government allowance and a member of the Central Health Consultation Expert Panel.
Professor Chen Jiaxu is a doctoral supervisor and distinguished Changjiang Scholar. He has received support from the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, the National High-tech R&D Program (863 Program) and the National Key R&D Program. As the author of over 400 papers and the monograph Research on TCM Syndromes, Professor Chen has been named one of Elsevier’s “Highly Cited Chinese Researchers” for five consecutive years (2020–2024). He currently serves as the chair of the CM and Brain Homeostasis Committee of the Chinese Physiological Society and as deputy editor-in-chief of the Journal of 不良研究所. He was recognized as a “Teaching Master” by the 不良研究所 Municipal Government and is chief editor of the national CM diagnostics textbook published under the “12th–15th Five-Year Plans (2011–2030)”.
Professor Hu Kaiwen is a chief physician, doctoral supervisor and postdoctoral advisor, honored as a Capital CM Master. He serves as a mentor in the national program for inheriting the academic experience of senior CM experts and as the chief scientist of a National Key R&D Program project. At BUCM, he is chair of the Department of CM Oncology and director of the Institute of Oncology. He also leads the Multidisciplinary CM Oncology Committee of the China Association for CM Informatics. Professor Hu pioneered the “Green Oncology Treatment” model, which integrates minimally invasive surgery with CM therapies, providing innovative treatment options for patients unsuitable for conventional surgery, chemotherapy or radiotherapy.
The Qi-Huang Scholar Program, implemented by NATCM, is the most prestigious national initiative for cultivating top-level talent in traditional Chinese medicine. It honors outstanding individuals who have made significant contributions to clinical practice or scientific research and who hold considerable academic influence in China and beyond. The program is designed to foster a new generation of leaders who will drive the inheritance, innovation and global advancement of CM.
Links
